These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 24865582)

  • 1. Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway.
    Echevarría-Vargas IM; Valiyeva F; Vivas-Mejía PE
    PLoS One; 2014; 9(5):e97094. PubMed ID: 24865582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
    Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
    Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis.
    Liu S; Fang Y; Shen H; Xu W; Li H
    Acta Biochim Biophys Sin (Shanghai); 2013 Sep; 45(9):756-62. PubMed ID: 23824073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
    Zhang X; Huang L; Zhao Y; Tan W
    Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
    Wu D; Lu P; Mi X; Miao J
    Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
    Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
    Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
    Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling.
    Li J; Pan C; Boese AC; Kang J; Umano AD; Magliocca KR; Yang W; Zhang Y; Lonial S; Jin L; Kang S
    Clin Cancer Res; 2020 Jul; 26(14):3843-3855. PubMed ID: 32341033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. XIAP associated factor 1 (XAF1) represses expression of X-linked inhibitor of apoptosis protein (XIAP) and regulates invasion, cell cycle, apoptosis, and cisplatin sensitivity of ovarian carcinoma cells.
    Zhao WJ; Deng BY; Wang XM; Miao Y; Wang JN
    Asian Pac J Cancer Prev; 2015; 16(6):2453-8. PubMed ID: 25824780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
    Ge T; Liu T; Guo L; Chen Z; Lou G
    Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoration of microRNA-708 sensitizes ovarian cancer cells to cisplatin via IGF2BP1/Akt pathway.
    Qin X; Sun L; Wang J
    Cell Biol Int; 2017 Oct; 41(10):1110-1118. PubMed ID: 28685895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance.
    Brozovic A; Fritz G; Christmann M; Zisowsky J; Jaehde U; Osmak M; Kaina B
    Int J Cancer; 2004 Dec; 112(6):974-85. PubMed ID: 15386344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
    Zhang Y; Huang S; Guo Y; Li L
    Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells.
    Rabelo-Fernández RJ; Santiago-Sánchez GS; Sharma RK; Roche-Lima A; Carrion KC; Rivera RAN; Quiñones-Díaz BI; Rajasekaran S; Siddiqui J; Miles W; Rivera YS; Valiyeva F; Vivas-Mejia PE
    Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-155 promotes apoptosis in SKOV3, A2780, and primary cultured ovarian cancer cells.
    Chen W; Huang L; Hao C; Zeng W; Luo X; Li X; Zhou L; Jiang S; Chen Z; He Y
    Tumour Biol; 2016 Jul; 37(7):9289-99. PubMed ID: 26779627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving.
    Wang DY; Li N; Cui YL
    Cancer Res Treat; 2020 Jul; 52(3):798-814. PubMed ID: 32124583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
    Fraser M; Bai T; Tsang BK
    Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
    Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
    PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-183 promotes proliferation and invasion in oesophageal squamous cell carcinoma by targeting programmed cell death 4.
    Ren LH; Chen WX; Li S; He XY; Zhang ZM; Li M; Cao RS; Hao B; Zhang HJ; Qiu HQ; Shi RH
    Br J Cancer; 2014 Nov; 111(10):2003-13. PubMed ID: 25211657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.